Ibogaine is not legal in the U.S., mostly for financial reasons and Big Pharma wanting to profit from disease, but it’s legal in many countries such as Canada, the Netherlands, Costa Rica, Mexico, Brazil and more. Since it’s not legal or regulated, it’s harder to test and get funds for clinical studies and further research. But since the 60s there have been some ibogaine advocates that have helped push the cause further with various published studies, some on animals while others on people. The ibogaine studies tested various things such as how the brain reacts to ibogaine anti-addictive properties, what happens to serotonin and dopamine levels in the brain and even how addicts react long-term.
For example, one study from 2000, showed that when a single dose of ibogaine which is anywhere from 500 to 800 mg was given to 27 cocaine- and opioid addicts, it resulted in a significant decrease of cravings and depressed symptoms. Another study by MAPS, suggests that ibogaine can prevent most patients from relapsing within two months of treatment.
Ibogaine Research From Brazil
Scientists in South America did a research in a substance abuse ( cocaine, alcohol, marijuana and tobacco) in Brazil that sends patients to a private hospital where physicians oversee an ibogaine treatment. Emotional support was provided but no other influence related to the ibogaine experience. In follow-ups, psychological therapy was provided and more ibogaine doses were given. The goal behind this ibogaine research in Brazil was to see if an ibogaine treatment was effective in treating addiction to other substances not just opioids like heroin. The data showed that yes it was! 61% of patients were completely abstinent after eight months, and longer average periods of abstinence with multiple substances. This ibogaine research also showed that there were no ill effects in any of the 75 patients, other than typical ibogaine treatment effects like nausea and confusion.
Ibogaine Research in New Zealand and Mexico
Although data is still being gathered for two studies by MAPS, they will uncover how ibogaine affected overall quality of life for patients, including status in employment, social relationships, feelings of depression, and changes in emotional intelligence. Preliminary results show a remarkable 20 – 50% rate of abstinence on follow-up a year later.
There are many other studies on ibogaine, however no mainstream consensus. Although most researchers agree it inhibits the reuptake of the neurotransmitter serotonin. Every ibogaine experience is a different journey, watch the Ibogaine Clinic for testimonials to see for yourself.